Print version of this report
TGA Action ID RC-2026-RN-00906-1
Type of Product Medical Device
Product Name/Description Aptiva CTD Essential Reagent. An in vitro diagnostic medical device (IVD).

Part Number: 723100

All lot numbers
ARTG Number 199418
Action Type Product Correction
Action Level Hospital
Hazard Classification Class II
Reason for the Action Werfen Australia has identified two problems affecting the Aptiva CTD Essential Reagent

1. The Instructions for Use for Aptiva CTD Essential Reagent (Part No. 723100), document 723100.DI_EN.C, Revision 09, released in July 2026, state that the assay is intended for use in adult and paediatric populations. Available performance evaluation data are insufficient to establish performance in paediatric populations. The IFU has been revised to remove the paediatric population claim and specify use in adult populations.

2. The shelf life of Aptiva CTD Essential Reagent has been reduced from 24 months to 12 months.

Use of the product beyond its supported shelf life, or in paediatric patients, may produce an incorrect test result.

To date, no complaints or adverse events related to these problems have been reported in Australia or worldwide.
Instructions for Customers/Users Problem 1:
- An updated IFU removing the paediatric claim is available on the Werfen electronic IFU website.
- Discontinue testing paediatric samples with this product.

Problem 2:
- Customers are to be aware that all future lots of this product now have a 12-month shelf-life.

No routine retrospective review of previously reported paediatric results is required as a result of this intended-use correction.
Action Commencement Date 18/11/2026
Responsible Entity Werfen Australia Pty Ltd
Contact Information 1300 369 132 - Werfen Australia Customer Service